Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGLM-NH2 + SSSR Eye Drops for Neurotrophic Keratopathy in Leprosy Sequelae
jRCTs071220053Completed
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of FGLM-NH2 + SSSR peptides in neurotrophic keratitis (NK), sponsored by Ministry of Health, Labour and Welfare. Primary endpoint: Improvement of neuroparalytic (neurotrophic) keratopathy. Started Oct 2022; status: completed.
02
Drugs
FGLM-NH2 + SSSR peptides
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on jRCTs071220053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220053.